Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 2
2015 2
2016 5
2017 3
2018 2
2019 3
2020 1
2021 3
2022 4
2023 2
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacokinetic and dose-finding study of osimertinib in patients with impaired renal function and low body weight.
Fujiwara Y, Makihara R, Hase T, Hashimoto N, Naito T, Tsubata Y, Okuno T, Takahashi T, Kobayashi H, Shinno Y, Zenke Y, Ikeda T, Hosomi Y, Watanabe K, Kitazono S, Sakiyama N, Makino Y, Yamamoto N. Fujiwara Y, et al. Among authors: watanabe k. Cancer Sci. 2023 May;114(5):2087-2097. doi: 10.1111/cas.15736. Epub 2023 Feb 14. Cancer Sci. 2023. PMID: 36704833 Free PMC article.
Opioid-induced nausea and vomiting: a dexamethasone multicentre prospective study.
Takagi Y, Ota S, Yomota M, Ishihara M, Hosomi Y, Watanabe K, Honda T, Kato Y, Kawai S, Sakamoto T, Haruyama T, Aruga E, Seki N. Takagi Y, et al. Among authors: watanabe k. BMJ Support Palliat Care. 2024 Jan 8;13(e3):e741-e742. doi: 10.1136/bmjspcare-2022-003692. BMJ Support Palliat Care. 2024. PMID: 35443972 No abstract available.
Pharmacokinetic and pharmacogenomic analysis of low-dose afatinib treatment in elderly patients with EGFR mutation-positive non-small cell lung cancer.
Mizugaki H, Oizumi S, Fujita Y, Harada T, Nakahara Y, Takashina T, Ko R, Watanabe K, Hotta T, Minemura H, Saeki S, Asahina H, Nakamura K, Nakamura H, Hosoda F, Yagishita S, Hamada A. Mizugaki H, et al. Among authors: watanabe k. Eur J Cancer. 2022 Jan;160:227-234. doi: 10.1016/j.ejca.2021.10.024. Epub 2021 Nov 30. Eur J Cancer. 2022. PMID: 34862083
Efficacy and safety of first-line osimertinib treatment and postprogression patterns of care in patients with epidermal growth factor receptor activating mutation-positive advanced non-small cell lung cancer (Reiwa study): study protocol of a multicentre, real-world observational study.
Watanabe K, Yoh K, Hosomi Y, Usui K, Naka G, Kishi K, Uemura K, Ohashi Y, Kunitoh H. Watanabe K, et al. BMJ Open. 2022 Jan 4;12(1):e046451. doi: 10.1136/bmjopen-2020-046451. BMJ Open. 2022. PMID: 34983748 Free PMC article.
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.
Uehara Y, Hakozaki T, Kitadai R, Narita K, Watanabe K, Hashimoto K, Kawai S, Yomota M, Hosomi Y. Uehara Y, et al. Among authors: watanabe k. Transl Lung Cancer Res. 2022 Feb;11(2):135-149. doi: 10.21037/tlcr-21-815. Transl Lung Cancer Res. 2022. PMID: 35280320 Free PMC article.
28 results